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OBJECTIVES: PEGylated interferon beta-1a (PEG-IFN beta-1a) is being developed for
the treatment of relapsing-remitting multiple sclerosis (MS). PEGylated drugs are
commonly used in other therapeutic areas, including oncology and hepatitis, but
none are currently approved for MS. This study was conducted to gain a better
understanding of the published humanistic and patient quality of life benefits of
PEGylated drugs currently available for the treatment of other diseases.METHODS:
A comprehensive search of medical literature published between 1985 and 2010
was conducted using PubMed/MEDLINE and supplemental searches. Reviewed ref-
erenceswere prospective or retrospective studies reporting the tolerability, health-
related quality of life (HRQOL), convenience, compliance, and patient preferences
associated with PEGylated drugs. Only studies comparing PEGylated drugs to their
corresponding non-PEGylated counterparts in the same therapeutic area were in-
cluded in the analysis. RESULTS: Fifty-nine articles and 12 conference abstracts
were reviewed. Eleven PEGylated drugswere identified, 6 ofwhich had correspond-
ing non-PEGylated counterparts. All 6 of these PEGylated drugs were administered
less frequently than their non-PEGylated counterparts yet exhibited similar or
greater efficacy, along with greater patient convenience. PEGylated drugs were
generally tolerated as well as or better than their non-PEGylated counterparts. In
HRQOL studies, patientswho received PEGylated drugs reported betterHRQOL than
those receiving non-PEGylated drugs across a broad spectrum of domains, as well
as in global HRQOL scores. For studies measuring quality-adjusted life-years
(QALYs), PEGylated drugs were reported to produce more QALYs than their non-
PEGylated counterparts. While few studies have evaluated patient medication
compliance and patient preference/satisfaction, the published results of these
studies also favor PEGylated drugs.CONCLUSIONS: PEGylated drugs are reported to
be tolerated at least as well as their non-PEGylated counterparts and to be associ-
ated with higher HRQOL and greater patient preference/satisfaction, convenience,
and compliance. PEG-IFN beta-1a may offer similar benefits to patients with MS.
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OBJECTIVES: In light of the apparent disconnect between traditional measures of
societal well-being such as GDP and reported levels of happiness, governments
globally are turning their attention to alternative subjectivemeasures ofwell-being
(SWB) to aid policy decisions. In the context of health, there is therefore growing
interest in understanding how measures of health-related quality of life (HRQoL),
widely used in health technology appraisal, relates to SWB, and whether SWB
could provide a sound basis for resource allocation decisions in health and other
sectors in the future. This pilot study investigates the relationship betweenHRQoL,
as measured by EQ-5D, and SWB in Parkinson’s Disease (PD) and the extent to
which patients’ self-reported health can be used to predict their subjective
wellbeing.METHODS: A paper questionnaire including EQ-5D, four key SWB ques-
tions taken from the Office for National Statistics Integrated Household Survey in
England and other demographic details was distributed to people with PD in the
United Kingdom. Responses were used to estimate multiple regression models
explaining SWB using each of the EQ-5D Index (using UK weights), EQ-5D dimen-
sions and EQ-VAS andpatient socio-demographic characteristics.RESULTS:A total
of 276 questionnaires were distributed and 183 responses received. The EQ-5D
Index was generally a weak predictor of SWB in terms of life satisfaction, life being
worthwhile, and happiness (adjusted R2 from 0.13 - 0.26), but EQ-VAS performed
better (adjusted R2 from 0.28-0.40). The EQ-5D anxiety/depression dimensionwas a
reasonable predictor of anxiety (adjusted R20.34). CONCLUSIONS: The findings
imply that EQ-VAS and some dimensions of the EQ-5D, together with key demo-
graphic data such as household status, could potentially be used to predict SWBe.g.
via mapping. However further empirical research into the relationship between
SWB and EQ-5D longitudinally, and in different disease areas, is required to cor-
roborate these findings, and further standardisation of SWB measures is recom-
mended.
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OBJECTIVES: To assess and report utilization and patient perceptions of migraine
prophylaxis therapy in chronic migraine (CM) and episodic migraine (EM).
METHODS: A web-based survey evaluating the burden of migraine was adminis-
tered to 32,782 subjects from 6 countries. Responders (n16,663) were eligible for
themain questionnaire if they were 18 years of age, reported at least 1 headache
during the last 3 months, and reported symptoms meeting diagnostic criteria for
migraine. Eligible responders (n 1,183) were classified as CM or EM, based on
reported headache frequency (15 and 15 headache days per month, respec-
tively). For four medication classes (antidepressants, antiepileptics, beta blockers
and calcium channel blockers), subjects reporting current usage rated their overall
satisfaction, perception of headache improvement and experience with adverse
effects. RESULTS: Respondents (n1,165) were predominantly female (75.0%) with
a mean age of 43.6  12.2 years. 42.3% (n493) of subjects were classified as CM.
More CM subjects reported ever taking prophylaxis (CM vs. EM: 62.8% vs. 39.9%,
p0.001) and trying two ormore prophylactic therapies (CMvs. EM: 46.0% vs. 22.8%,
p0.001). Adjusting for age and gender, EM subjects were more likely to agree or
strongly agree that their headaches had improved and that theywere satisfiedwith
their prophylactic therapy (respectively: OR 2.1, p 0.001; OR 1.9, p 0.004). Adjusted
multivariate analyses showed similar results, but statistical significancewasmain-
tained for headache improvement only (respectively: OR 2.0, p 0.026; OR 1.2, p
0.584). CONCLUSIONS: These findings support previous reports that most mi-
graineurs, including many CM patients, have never tried prophylaxis. Though mi-
graine type (chronic vs. episodic) appears to influence patient perceptions of pro-
phylaxis, perceptions are multifactorial.
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OBJECTIVES: Well-defined attributes are a cornerstone of choice-format conjoint
studies (discrete-choice experiments). However, little is known about how ill-de-
fined attributes affect the quality of stated-choice data. The objective of this study
was to evaluate choice responseswhen attribute levels in the choice options do not
align with a respondent’s personal current reference condition.METHODS: A total
of 193 US adults with self-reported epilepsy who reported taking antiepileptic
drugs (AEDs) to treat their seizures completed a web-enabled, choice-format con-
joint survey. Respondents responded to a series of choice questions to assess their
willingness to add another AED to control their seizures. Consistentwith endpoints
measured in a clinical trial, the efficacy attributewas defined as a 100%, 75%, 50% or
25% reduction in the number of seizures relative to the respondent’s current ref-
erence condition: each respondent’s own number of seizures over the last 3
months. Other treatment outcomes included short-term and long-term side ef-
fects, difficulty urinating, weight change, dosing frequency, and personal cost of
the add-on AED. RESULTS: Respondents’ current treatment generally achieved
good seizure control. Only one-third of the respondents reported having any sei-
zures and 20% reported having only 1 to 3 seizures. Nevertheless, aggregate pref-
erence estimates for the 100%, 75%, 50% or 25% seizure-reduction levels were cor-
rectly ordered, statistically different from each other (with one exception), and
were of sensible magnitudes relative to other treatment outcomes. Statistical tests
indicated that there was no difference in preferences between respondents with
4 seizures and those with 4 or more seizures. CONCLUSIONS: We have no infor-
mation about how patients with few or no seizures evaluated meaningless per-
centage reductions in their reference condition. Their reinterpretation of the attri-
bute levels, however, resulted in the same preference estimates as those for whom
the levels were consistent with their experience. Thus, our respondents may just
fix our mistakes.
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OBJECTIVES: To demonstrate the use of trade-off preferences from a conjoint anal-
ysis in a structured framework for benefit-risk assessment ofmigraine treatments.
METHODS: Efficacy and safety endpoints from a hypothetical clinical study of
triptans in acute migraine were developed using the BRAT benefit-risk Framework
to identify and define endpoints as treatment benefits or harms. This decision
framework provides a foundation for selecting, organizing, understanding and
summarizing evidence relevant to benefit-risk decisions. To assess the relative
importance of these benefits and harms, we used a choice-format conjoint survey,
also known as discrete-choice experiment, to elicit migraineurs’ preferences for
clinical endpoints and to develop a set of importance weights for each endpoint.
These importance weights were then used to weigh mock clinical evidence and
demonstrate several means to assess the benefits and risks of triptans. We esti-
mated severalweightedmeasures of benefit-risk including incremental net clinical
benefit, the probability that benefit exceeds harm, and maximum acceptable risk.
RESULTS:A total of 201 self-reportedmigraineurs completed the conjoint-analysis
survey. The most important outcome evaluated by migraineurs was the chance of
dying from a myocardial infarction. The least important outcome was the chance
that a migraine would return 24 hours after taking medication. Preferences for
outcomes differed by gender. Weighted incremental net clinical benefit, the prob-
ability that benefit exceeds harm and maximum acceptable risk varied depending
on patient subgroup. CONCLUSIONS: Stakeholders routinely need to make judg-
ments about the relative value of benefits and risks associated with treatments.
Preference information is typically not explicitly used to aid in the evaluation of
clinical benefit and risk data. The use of preference information in the BRAT Frame-
work can help decision makers assess clinical evidence using a structured ap-
proach. The use of a variety of weighted benefit-risk measures provided several
perspectives by which decision makers can assess the decision.
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OBJECTIVES: To identify predictors of poor health-related quality of life (HRQoL) in
members of the free online PatientsLikeMe Epilepsy Community. METHODS: The
PatientsLikeMe Epilepsy Community (launched January 2010) allows patients with
epilepsy to record, monitor and share their socio-demographic and disease char-
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